Vivani Medical, Inc. is developing NPM-139 Semaglutide Implant, an ultra long-acting drug with potential Wegovy-level efficacy.
4 reports, 3 independent
Updated Jul 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vivani Medical, Inc. is developing NPM-139 Semaglutide Implant, an ultra long-acting drug with potential Wegovy-level efficacy.
How it developed
Newest first. Tap a step to see who reported it.- Novo Nordisk is evaluating Vivani's implant technology for weight management and health risks.Sub-event
Vivani Medical is developing a novel ultra long-acting implant for obesity treatment.1 source
Vivani Medical, Inc.'s CEO, Adam Mendelsohn, was mentioned on August 20, 2025.1 source
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireVivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-y
- GlobeNewswireVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical,
- BenzingaEXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenati